Impact of Trial Eligibility Criteria on Outcomes of 1183 Patients With Follicular Lymphoma Treated in the Real‐World Setting
European Journal of Haematology · 2025
DOI: 10.1111/ejh.14373 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Tine Litske Bennedsen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Antineoplastic Combined Chemotherapy Protocols, Patient Selection, Eligibility Determination. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Danish Cancer Society Research Center, Danish Data Science Academy.
Abstract (Originalsprache)
The development of new first‐line treatments for patients with follicular lymphoma (FL) is becoming increasingly challenging due to already excellent survival outcomes. The present study investigated the outcomes of patients with FL who underwent contemporary first‐line therapies but would not have been eligible for inclusion in recent trials and explored how commonly used in/exclusion criteria impacted their survival outcomes. This study included adult patients diagnosed with FL in the period 2000–2018 registered in the Danish Lymphoma Registry. Through searches on ClinicalTrials.gov , four recent 1st line phase 3 randomized controlled trials with R‐Bendamustine, R‐CVP, and/or R‐CHOP as control or experimental arms were included. Inclusion and exclusion criteria for each trial were retrieved and categorized. Patients were then divided into trial‐eligible and ineligible groups according to blood test results correlated to organ function and ECOG performance score (PS). Survival outcomes were significantly worse among trial‐ineligible patients, with adjusted differences between trial‐eligible and ineligible patients of 12%–20% in five‐year overall survival (OS) overall. Inclusion criteria based on PS and renal function were the main drivers of OS differences. More inclusive trials will lead to faster recruitment and secure focus on developing medicines for the group of patients with the worst outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
- Department of Internal Medicine Thisted, Aalborg University Hospital, Thisted, Denmark.
- Department of Mathematical Sciences, Aalborg University, Aalborg, Denmark.
- Department of Hematology, Copenhagen University Hospital, Copenhagen, Denmark.
- Mayo Clinic Rochester - Division of Hematology, Rochester, Minnesota, USA.
- Department of Hematology, Vejle Hospital, Vejle, Denmark.
ORCID-Profile: Tine Litske Bennedsen, Mikkel Runason Simonsen, Michael Roost Clausen, Lars Møller Pedersen
Förderung
- Danish Cancer Society Research Center
- Danish Data Science Academy
Zitieren
APA
Bennedsen, T. L., Simonsen, M. R., Jensen, P., Brown, P., Josefsson, P., Khurana, A., Maurer, M., Clausen, M. R., Dessau-Arp, A., Jørgensen, J. B., Jørgensen, J., Larsen, T. S., Pedersen, L. M., Jakobsen, L. H., & El-Galaly, T. C. (2025). Impact of Trial Eligibility Criteria on Outcomes of 1183 Patients With Follicular Lymphoma Treated in the Real‐World Setting. European Journal of Haematology. https://doi.org/10.1111/ejh.14373
Vancouver
Bennedsen TL, Simonsen MR, Jensen P, Brown P, Josefsson P, Khurana A, et al. Impact of Trial Eligibility Criteria on Outcomes of 1183 Patients With Follicular Lymphoma Treated in the Real‐World Setting. European Journal of Haematology. 2025. doi:10.1111/ejh.14373
BibTeX
@article{Bennedsen2025,
author = {Bennedsen, Tine Litske and Simonsen, Mikkel Runason and Jensen, Paw and Brown, Peter and Josefsson, Pär and Khurana, Arushi and Maurer, Matthew and Clausen, Michael Roost and Dessau-Arp, Andriette and Jørgensen, Jennifer Bøgh and Jørgensen, Judit and Larsen, Thomas Stauffer and Pedersen, Lars Møller and Jakobsen, Lasse Hjort and El-Galaly, Tarec Christoffer},
title = {Impact of Trial Eligibility Criteria on Outcomes of 1183 Patients With Follicular Lymphoma Treated in the Real‐World Setting},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.14373}
}
EUVIMED